Details for Patent: 8,309,125
✉ Email this page to a colleague
Title: | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Abstract: | A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described. |
Inventor(s): | Kositprapa; Unchalee (Davie, FL), Nangia; Avinash (Weston, FL), Cardinal; John (Tamarac, FL), Goldfarb; Robert I. (Golden Beach, FL) |
Assignee: | Watson Pharmaceuticals, Inc. (Corona, CA) |
Filing Date: | Jul 14, 2010 |
Application Number: | 12/835,945 |
Claims: | 1. A method for preparing a sustained release oral tablet comprising: a) forming a controlled release metformin hydrochloride tablet comprising 500 mg to 1000 mg of metformin; b) preparing an immediate release coating solution comprising: i) pioglitazone hydrochloride; ii) water; iii) an organic solvent selected from the group consisting of acetone, isopropyl alcohol, methanol or ethanol; iv) a binder; v) optionally a surfactant; vi) optionally a pore forming agent wherein the ratio of water to organic solvent is 50:50 to 2:98 and the ratio of binder to pioglitazone hydrochloride is 1:9 to 1:11; c) applying the immediate release coating solution to the controlled release metformin hydrochloride tablet so that when tested in a United States Pharmacopeia (USP) Type 2 apparatus at 75 rpm in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37.degree. C., not less than 75% of the pioglitazone hydrochloride is released from the sustained release tablet in 30 minutes. 2. The method of claim 1 wherein not less than 95% of the pioglitazone hydrochloride is released from the sustained release tablet in 30 minutes. 3. The method of claim 1 wherein the sustained release tablet is prepared without a gelling polymer. 4. The method of claim 1 wherein the controlled release metformin hydrochloride tablet is formed by: A) mixing the metformin hydrochloride with at least one pharmaceutically acceptable excipient; B) compressing the mixture of step (A) into a tablet; and C) coating the tablet of step (B) with a membrane. 5. A tablet prepared by the method of claim 1. 6. A method for preparing a sustained release oral tablet comprising: i) forming a controlled release metformin hydrochloride tablet comprising 500 mg to 1000 mg of metformin and without a gelling polymer comprising the steps of: a) mixing the metformin hydrochloride with at least one pharmaceutically acceptable excipient; b) compressing the mixture of step (a) into a tablet; and c) coating the tablet of step (b) with a membrane; ii) preparing an immediate release coating solution comprising: a) pioglitazone hydrochloride; b) water; c) an organic solvent selected from the group consisting of acetone, isopropyl alcohol, methanol or ethanol; d) a binder; e) optionally a surfactant; f) optionally a pore forming agent wherein the ratio of water to organic solvent is 50:50 to 2:98 and the ratio of binder to pioglitazone hydrochloride is 1:9 to 1:11; iii) applying the immediate release coating solution to the membrane of the controlled release metformin hydrochloride tablet so that when tested in a United States Pharmacopeia (USP) Type 2 apparatus at 75 rpm in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37.degree. C., not less than 95% of the pioglitazone hydrochloride is released from the sustained release tablet in 30 minutes. 7. A tablet prepared by the method of claim 6. |